BIO-PATH HOLDINGS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
BPTH$0.21-66.8%Stored close · as of Feb 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
(In thousands, except per share amounts)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, | ||||||||||||
| · 2024 · 2023 · 2024 · 2023 | ||||||||||||
| · · · · | ||||||||||||
| Operating expenses · · · · | ||||||||||||
| · · · · | ||||||||||||
| Research and development | | $1,317 | | $2,292 | | $5,478 | | $9,332 | ||||
| General and administrative | | 1,317 | | 984 | | 3,889 | | 3,478 | ||||
| | | | | | | | | | ||||
| Total operating expenses | | 2,634 | | 3,276 | | 9,367 | | 12,810 | ||||
| | | | | | | | | | ||||
| Net operating loss | | $(2,634) | | $(3,276) | | $(9,367) | | $(12,810) | ||||
| | | | | | ||||||||
| Other income | | | | | ||||||||
| Change in fair value of warrant liability | | | 515 | | | 72 | | | 2,216 | | | 72 |
| Interest income | | 4 | | 5 | | 10 | | 32 | ||||
| | | | | | | | | | ||||
| Total other income | | 519 | | 77 | | 2,226 | | 104 | ||||
| | | | | | ||||||||
| Net loss | | $(2,115) | | $(3,199) | | $(7,141) | | $(12,706) | ||||
| | | | | | ||||||||
| Net loss per share, basic and diluted | | $(0.70) | | $(6.36) | | $(4.05) | | $(29.34) | ||||
| | | | | | | | | | | | | |
| Basic and diluted weighted average number of common shares outstanding | | 3,017 | | 503 | | 1,763 | | 433 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.